Top

Published in:

01-12-2014 | Original Article

Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer

Authors: Jianwen Wang, Xiaodong Zhang, Ping Wei, Junhui Zhang, Yinong Niu, Ning Kang, Yuxiang Zhang, Weili Zhang, Nianzeng Xing

Published in: World Journal of Urology | Issue 6/2014

Abstract

Purpose

To explore the potential correlation and prognostic value of Livin, Survivin and Caspase 3 expression in non-muscle-invasive bladder cancer (NMIBC).

Methods

We prospectively examined the simultaneous expression of Livin, Survivin and Caspase 3 with immunohistochemistry in the paraffin blocks of 138 patients who underwent transurethral resection, and ten cases of normal bladder specimens were studied as the control group. During a 48-month follow-up, clinical pathologic factors including gender, age, pathology stage, histology grade, adjuvant therapy and recurrence time were recorded. The curves for recurrence-free survival (RFS) were estimated by the Kaplan–Meier method, and the relationship between these proteins’ expression and clinical pathologic factors was analyzed with the Cox regression model.

Results

Livin and Survivin showed a high expression (H-exp) level of 65.22 and 71.01 % in NMIBC, respectively, whereas Caspase 3 expression level was 50.72 %, and H-exp level of Livin and Survivin were 72.7 and 80.0 % in pT1 stage, respectively, which were proved to be higher than that in pTa/Tis ratio (P < 0.05). The relation between the H-exp and low-expression (L-exp) groups of Livin and Survivin and RFS were found statistically significant (P < 0.05). Conversely, there was better RFS in H-exp Caspase 3 group than in L-exp group (P < 0.05). A risk score was developed on the basis of all three biomarkers to estimate the prognosis of NMIBC patients, and those expressing high Survivin and Livin and low Caspase 3 had a significant shorter RFS time (P < 0.05).

Conclusions

Livin, Survivin and Caspase 3 may be valuable as promising indicators of early recurrence in NMIBC.

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29PubMedCrossRef

Parkin MD, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626–630PubMedCrossRef

Ashhab Y, Alian A, Polliack A et al (2001) Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 495:56–60PubMedCrossRef

Karam JA, Lotan Y, Ashfaq R et al (2007) Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70:482–486PubMedCrossRef

Alnemri ES, Livingston DJ, Nicholson DW et al (1996) Human ICE/CED-3 protease nomenclature. Cell 87:171–172PubMedCrossRef

Dai CH, Li J, Shi SB et al (2010) Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 40:327–335PubMedCrossRef

Gazzaniga P, Gradilone A, Giuliani L et al (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14:85–90PubMedCrossRef

Smolewski P, Robak T (2011) Inhibitors of apoptosis protein (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med 11:633–649PubMedCrossRef

10.

Chen N, Gong J, Chen X et al (2009) Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinic pathologic significance. Hum Pathol 40:950–956PubMedCrossRef

11.

Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York, pp 199–202

12.

Ebele JN, Sauter G, Epstein JI et al (2004) World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs. IARC Press, Lyon, pp 90–91

13.

Yin W, Chen N, Zhang Y et al (2006) Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 19:1487–1497PubMed

14.

Atlasi Y, Mowla SJ, Ziaee SA (2009) Differential expression of survivin and its splice variants, survivin-DEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev 32:308–313PubMedCrossRef

15.

Weikert S, Christoph F, Schrader M et al (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116:100–104PubMedCrossRef

16.

Schultz I, Kiemeney L, Witjes JA et al (2003) Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23:3327–3331PubMed

17.

Birkhahn M, Mitra AP, Williams AJ et al (2010) Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 57:12–20PubMedCentralPubMedCrossRef

18.

Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs 20:646–658PubMedCrossRef

19.

Yang D, Song X, Zhang J et al (2010) Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin 42:137–144PubMedCrossRef

20.

Liu HB, Kong CZ, Zeng Y et al (2009) Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol 27:271–283CrossRef

21.

Xi RC, Sheng YR, Chen WH et al (2013) Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 107:550–554PubMedCrossRef

22.

Caldas H, Honsey LE, Altura RA (2005) Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4:11–15PubMedCentralPubMedCrossRef

23.

Ceballos-Cancino G, Espinosa M, Maldonado V et al (2007) Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 26:7969–7975CrossRef

24.

Giodini A, Kallio MJ, Wall NR et al (2002) Regulation of micro- tubule stability and mitotic progression by survivin. Cancer Res 62:2462–2467PubMed

25.

Tu SP, Jiang XH, Lin MC et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724–7732PubMed

26.

Margulis V, Lotan Y, Shariat SF (2008) Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 26:59–65PubMedCrossRef

27.

Wang H, Xi X, Kong X et al (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 130:487–490PubMedCrossRef

28.

Salvesen GS (2002) Caspases: opening the boxes and interpreting the arrow. Cell Death Differ 9:3–5PubMedCrossRef

29.

Liu C, Wu X, Luo C et al (2010) Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3. J Exp Clin Cancer Res 29:63–68PubMedCrossRef

30.

Karam JA, Lotan Y, Karakiewicz PI et al (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8:128–136PubMedCrossRef

Title: Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer
Authors: Jianwen Wang
Xiaodong Zhang
Ping Wei
Junhui Zhang
Yinong Niu
Ning Kang
Yuxiang Zhang
Weili Zhang
Nianzeng Xing
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 6/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1246-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2014

High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study

Modified single-port minilaparoscopic extraperitoneal repair for pediatric hydrocele: a single-center experience with 279 surgeries

New technique for prostate volume assessment

Long-term evaluation of oncologic and functional outcomes after laparoscopic open-assisted radical cystectomy: a matched-pair analysis

Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study

Comment on “Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study”